A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2017 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 25 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 10 Jun 2017 Biomarkers information updated